Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BNT166a

Vaccine (mRNA vaccine) · Immune activation, directed at orthopoxvirus VP37 (F13L) · developed by BioNTech

Phase 2 Most advanced trial
BNTX Developer
1 Registered trials

What is BNT166a?

BNT166a is an investigational vaccine given by intramuscular injection into the deltoid muscle. It is studied for prevention of mpox, smallpox and orthopoxvirus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Targets
orthopoxvirus VP37 (F13L) (antigen)
Mechanism
Immune activation, directed at orthopoxvirus VP37 (F13L)
Therapy area
Infectious disease
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07379580 Phase 2 Mpox (Monkeypox) Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mpox (Monkeypox)Orthopoxvirus InfectionSmallpox

More from BioNTech

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind BNT166a

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.